Abstract
Aim: There are many people with type 2 Diabetes Mellitus (T2DM) worldwide. Rouxen- Y Gastric Bypass (RYGB) is an effective surgery for treating T2DM with beneficial effects on β cell metabolism. However, the mechanism of how RYGB affects the pancreas, is not clear. We focused on metabolic changes in the pancreas of rats following RYGBand to investigate complex postoperative pancreatic metabolic reprogramming and to understand how RYGB improves islet function.
Methods: We performed RYGBonstreptozotocin-induced male T2DM rats. Then we measured indicators such as weight, fasting GLU, etc. After 10 weeks, pancreatic tissues were removed to identify and quantify differentially expressed proteins. Furthermore, functional analysis of these proteins and their associated pathways was conducted by bioinformatics methods.
Results: After surgery, 451 differentially expressed proteins associated with the mechanism ofRYGB were identified. Protein levels of regenerating islet-derived protein 3 (Reg3A), cell division cycle-associated protein 2 (CDCA2), and ADP-ribosylation factor 1 (Arf1) varied greatly, and Arf1 may be a point target in diabetes.
Conclusion: This research shows that RYGB could treat T2DM through changes in the pancreatic proteins. It will give some new insight into the molecular mechanism behind the effect of RYGB.
Keywords: T2DM, RYGB, proteomics, pancreatic protein, reg3A, CDCA2, Arf1.
Current Proteomics
Title:iTRAQ-Based Proteomic Analysis of the Rat Pancreas Following Gastric Bypass Surgery
Volume: 18 Issue: 4
Author(s): Zhuolin Xie, Lu Bai, Xiang Gao, Liyong Zhu, Shaihong Zhu, Weizheng Li*Pengzhou Li*
Affiliation:
- Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan,China
- Department of General Surgery, Third Xiangya Hospital, Central South University, Changsha 410013, Hunan,China
Keywords: T2DM, RYGB, proteomics, pancreatic protein, reg3A, CDCA2, Arf1.
Abstract:
Aim: There are many people with type 2 Diabetes Mellitus (T2DM) worldwide. Rouxen- Y Gastric Bypass (RYGB) is an effective surgery for treating T2DM with beneficial effects on β cell metabolism. However, the mechanism of how RYGB affects the pancreas, is not clear. We focused on metabolic changes in the pancreas of rats following RYGBand to investigate complex postoperative pancreatic metabolic reprogramming and to understand how RYGB improves islet function.
Methods: We performed RYGBonstreptozotocin-induced male T2DM rats. Then we measured indicators such as weight, fasting GLU, etc. After 10 weeks, pancreatic tissues were removed to identify and quantify differentially expressed proteins. Furthermore, functional analysis of these proteins and their associated pathways was conducted by bioinformatics methods.
Results: After surgery, 451 differentially expressed proteins associated with the mechanism ofRYGB were identified. Protein levels of regenerating islet-derived protein 3 (Reg3A), cell division cycle-associated protein 2 (CDCA2), and ADP-ribosylation factor 1 (Arf1) varied greatly, and Arf1 may be a point target in diabetes.
Conclusion: This research shows that RYGB could treat T2DM through changes in the pancreatic proteins. It will give some new insight into the molecular mechanism behind the effect of RYGB.
Export Options
About this article
Cite this article as:
Xie Zhuolin, Bai Lu , Gao Xiang, Zhu Liyong , Zhu Shaihong, Li Weizheng *, Li Pengzhou *, iTRAQ-Based Proteomic Analysis of the Rat Pancreas Following Gastric Bypass Surgery, Current Proteomics 2021; 18 (4) . https://dx.doi.org/10.2174/1570164617999201116153530
DOI https://dx.doi.org/10.2174/1570164617999201116153530 |
Print ISSN 1570-1646 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6247 |
Call for Papers in Thematic Issues
Machine Learning Based Computational Biology and Digital Medicine
Machine learning has become a major research topic with a wide range of applications, such as intelligent driving, public security, financial risk management, medical diagnosis, and computational biology. This Special Thematic Issue entitled: "Recent Trends in Machine Learning Based Computational Biology and Digital Medicine" aims to explore the scientific-technological frontiers ...read more
Mass spectrometry data acquisition and analysis for proteomics
The Thematic Issue on "Mass spectrometry data acquisition and analysis for proteomics" aims to explore the latest advancements and challenges in the field of proteomics through the lens of mass spectrometry. Proteomics, the large-scale study of proteins and their functions, plays a crucial role in understanding various biological processes and ...read more
![Wayfinder Image](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Lysophosphatidic Acid and Renal Fibrosis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) The Mechanism of Plantaginis Semen in the Treatment of Diabetic Nephropathy based on Network Pharmacology and Molecular Docking Technology
Endocrine, Metabolic & Immune Disorders - Drug Targets Phosphoproteins with Stability Against All Urinary Phosphatases as Potential Biomarkers in Urine
Protein & Peptide Letters Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Abatacept and Glomerular Diseases: The Open Road for the Second Signal as a New Target is Settled Down
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Potential Deployment of Angiotensin I Converting Enzyme Inhibitors and of Angiotensin II Type 1 and Type 2 Receptor Blockers in Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Carbon Monoxide in Renal Physiology, Pathogenesis and Treatment of Renal Disease
Current Pharmaceutical Design Pharmacological Management of Type 2 Diabetes Complications
Current Vascular Pharmacology Bioprocess and Bioreactor: Next Generation Technology for Production of Potential Plant-based Antidiabetic and Antioxidant Molecules
Current Medicinal Chemistry NO Signaling Through cGMP in Renal Tissue Fibrosis and Beyond: Key Pathway and Novel Therapeutic Target
Current Medicinal Chemistry Novel Treatments in Diabetic Nephropathy
Current Hypertension Reviews Mechanisms for Cardiorenal Protection of SGLT-2 Inhibitors
Current Pharmaceutical Design Vasomotor Effects of Iodinated Contrast Media: Just Side Effects?
Current Vascular Pharmacology Genome Study of Kidney Disease in the Age of Post Genome-Sequencing
Endocrine, Metabolic & Immune Disorders - Drug Targets NADPH Oxidases and Inflammatory Bowel Disease
Current Medicinal Chemistry Acute Toxicological and Histopathological Elucidation of <i>Rheum emodi</i> Rhizome Extract to Demonstrate Antidiabetic Activity in Alloxan-induced Diabetic Rats
Current Bioactive Compounds African Plants with Antidiabetic Potentials: Beyond Glycaemic Control to Central Nervous System Benefits
Current Diabetes Reviews Blood Pressure Management in Metabolic Syndrome
Current Hypertension Reviews Inflammation and Thrombophilia in Pregnancy Complications: Implications for Risk Assessment and Clinical Management
Cardiovascular & Hematological Disorders-Drug Targets Animal Models of Diabetes Mellitus: Relevance to Vascular Complications
Current Pharmaceutical Design